Advertisement

When more could be industry-driven: the case of the extracorporeal treatment of sepsis

  • Miet SchetzEmail author
  • Thomas Bein
Less is More in ICU

The actual and complex situation

Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, continues to have a distressingly high morbidity and mortality. This is especially the case in septic shock, a subset of sepsis with profound circulatory, cellular, and metabolic abnormalities [1]. Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) and the resultant production of inflammatory cytokines play an important role in the pathogenesis. Currently, no drugs are approved for the treatment of sepsis, because none of the candidate modulators of the sepsis immune response could show a beneficial effect on patient outcomes in large randomized controlled trials, illustrating the urgent need for new treatment approaches.

The idea of extracorporeal removal of evil substances (blood “purification”), resulting in restoration of the immune balance, has already been raised in the 1980s and rapidly found...

Notes

Compliance with ethical standards

Conflicts of interest

MS and TB declare having no conflict of interest related to this manuscript.

References

  1. 1.
    Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810CrossRefGoogle Scholar
  2. 2.
    Van Norman GA (2016) Drugs and devices: comparison of European and U.S. approval processes. JACC Basic Transl Sci 1:399–412CrossRefGoogle Scholar
  3. 3.
  4. 4.
  5. 5.
    Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, La Greca G, Inguaggiato P, Maggiore U, De Nitti C, Wratten ML, Ricci Z, Tetta C (2002) A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 30:1250–1255CrossRefGoogle Scholar
  6. 6.
    Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, Remuzzi G, GiViTI (2014) Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 4:e003536CrossRefGoogle Scholar
  7. 7.
  8. 8.
    Träger K, Skrabal C, Fischer G, Datzmann T, Schroeder J, Fritzler D, Hartmann J, Liebold A, Reinelt H (2017) Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass—a case series. Int J Artif Organs 40:240–249CrossRefGoogle Scholar
  9. 9.
    Friesecke S, Stecher SS, Gross S, Felix SB, Nierhaus A (2017) Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs 20(3):252–259CrossRefGoogle Scholar
  10. 10.
    Friesecke S, Träger K, Schittek GA, Molnar Z, Bach F, Kogelmann K, Bogdanski R, Weyland A, Nierhaus A, Nestler F, Olboeter D, Tomescu D, Jacob D, Haake H, Grigoryev E, Nitsch M, Baumann A, Quintel M, Schott M, Kielstein JT, Meier-Hellmann A, Born F, Schumacher U, Singer M, Kellum J, Brunkhorst FM (2017) International registry on the use of the CytoSorb® adsorber in ICU patients: study protocol and preliminary results. Med Klin Intensivmed Notfmed. 2017 Sept 4.  https://doi.org/10.1007/s00063-017-0342-5. (Epub ahead of print)
  11. 11.
    Schädler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, Marx G, Putensen C, Spies C, Jörres A, Quintel M, Engel C, Kellum JA, Kuhlmann MK (2017) The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS ONE 12:e0187015CrossRefGoogle Scholar
  12. 12.
    Hawchar F, Laslo I, Öveges N, Trasy D, Ondrik Z, Molnar Z (2019) Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care 49:172–178CrossRefGoogle Scholar
  13. 13.
    Poli EC, Rimmelé T, Schneider AG (2019) Hemoadsorption with CytoSorb®. Intensive Care Med 45:236–239CrossRefGoogle Scholar
  14. 14.
  15. 15.
    Korenstein D (2019) Medical overuse as a physician cognitive error: looking under the hood. JAMA Intern Med 179:26–27CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Cellular and Molecular Medicine, Clinical Department and Laboratory of Intensive Care MedicineKU Leuven UniversityLouvainBelgium
  2. 2.Department of AnesthesiaRegensburg University HospitalRegensburgGermany

Personalised recommendations